The next move when anti-TNF fails

Rheumatoid arthritis patients who don’t respond to an anti-TNF do better when they are switched to a non-TNF-targeted biologic, rather than trying another anti-TNF, French researchers have found.

Lead investigator Dr Jacques-Eric Gottenberg from Strasbourg University Hospital says although around a third of patients fail with an initial anti-TNF treatment, there have been very few observational studies of second-line strategies, and no randomised trials until now.